title: Clindamycin and rifampicin: No bull's eye without a target.
authors.affiliation: Médecine Interne et Maladies Infectieuses, Centre Hospitalier Universitaire de Poitiers, Poitiers, France; EA2694, Université Droit et Santé Lille 2, Lille, France; Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Hasselt, Belgium. Electronic address: beraudguillaume@gmail.com.
authors.forename: Guillaume
authors.initials: G
authors.lastname: Béraud
authors.affiliation: Médecine Interne et Maladies Infectieuses, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.
authors.forename: Gwenaël
authors.initials: G
authors.lastname: Le Moal
authors.affiliation: Pharmacie hospitalière, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.
authors.forename: Sophie
authors.initials: S
authors.lastname: Sury
authors.affiliation: Pharmacie hospitalière, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Venisse
mesh_terms: D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics*; D002981:Clindamycin / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D008297:Male; D010003:Osteoarthritis / Q000188:drug therapy*; D012293:Rifampin / Q000493:pharmacokinetics*; D044967:Serum / Q000737:chemistry*; D013203:Staphylococcal Infections / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D002981:Clindamycin; D012293:Rifampin